Tagged Articles

Bayer 283 articles

First Xarelto trial delayed due to NBA All Star game


The first bellwether trial in the massive multidistrict litigation (MDL) involving bleeding risks with the blood thinner Xarelto was scheduled to begin this month in the Eastern District of Louisiana, but the National Basketball Association (NBA) All Star game occurring in New Orleans at the same time pushed U.S. District Judge Eldon Fallon to delay trial until March. The Xarelto MDL under Judge Fallon has swelled to nearly 14,000 lawsuits since the it was first consolidated in December 2014. Last summer, Judge Fallon had scheduled the first cases to be tried, with the first to be tried in February. But the ... Read More

Real-world data shows Xarelto has greater bleeding risk than Pradaxa


The blockbuster blood thinner Xarelto, prescribed to millions of patients worldwide, may have a higher bleeding risk than its competitor Pradaxa, according to a study based on real-world data published in JAMA Internal Medicine. The study involved records on 118,000 Medicare patients with atrial fibrillation who were treated with either Pradaxa or Xarelto for the prevention of strokes associated with the heart ailment. When compared to patients treated with Pradaxa, the Xarelto group had significant increases in intracerebral hemorrhage, major extracranial bleeding, and gastrointestinal bleeding. Pharmaceuticals are approved for marketing in the U.S. after undergoing a series of clinical trials ... Read More

Xarelto makers test drug on patients with CAD, PAD


A study investigating the effectiveness of the blood thinner Xarelto in patients with coronary artery disease (CAD) or peripheral arty disease (PAD) was halted prematurely after an interim analysis showed the medication helped prevent heart attacks, strokes and cardiovascular death. But the study has yet to reveal the rate of bleeding events, a known side effect of Xarelto. CAD and PAD are conditions in which there is a narrowing and blocking of the arteries in various critical regions of the body. CAD affects the heart’s arteries whereas PAD usually affects the arteries in the legs, but can also be used ... Read More

There remains an unmet need for novel anticoagulant reversal agent


With the increasing popularity of new novel anticoagulants over the long-used warfarin for the prevention of strokes in atrial fibrillation and other blood clot-related conditions, there remains an unmet need for an antidote to reverse the blood thinning effects of the drugs in the event of a bleeding emergency. The new line of blood thinners were introduced in 2010 and include the direct thrombin inhibitor Pradaxa, and the oral factor Xa inhibitors Xarelto, Eliquis and Savaysa. All anticoagulants increase the risk of major uncontrolled bleeding and life-threatening bleeding events, including gastrointestinal bleeds, rectal bleeds, and brain bleeds. There are currently ... Read More

Risperdal, Xarelto mass tort programs dominate in Pennsylvania court system


Only two mass tort programs in Philadelphia’s Complex Litigation Center involving pharmaceuticals grew in 2016: the litigation involving the antipsychotic drug Risperdal and the blood thinner Xarelto. All other pharmaceutical mass torts lost between 6 and 100 percent of their inventory in 2016. As of Jan. 1, 5,601 pharmaceutical cases were pending in Philadelphia – nearly 200 more than were pending at the start of 2012, the year the court started implementing changes designed to clear its mass tort inventory. The Xarelto mass tort grew by 664 cases in 2016, bringing the total of cases pending to 1,214. The program ... Read More

Xarelto sales expected to boost J&J’s bottom line in 2017


Consumer health care products and medical devices generate billions of dollars for Johnson & Johnson. Its pharmaceutical offerings are expected to drive the company’s growth in the year ahead, with its blockbuster blood thinner Xarelto among the leaders of the pack, according to analyst Todd Campbell, owner of E.B. Capital Markets, LLC. Xarelto, manufactured by J&J unit Janssen Pharmaceuticals and Bayer, was approved in 2011 as the second in a new class of blood thinners competing with the long-used warfarin for the prevention of strokes in patients with atrial fibrillation. The medication is also used to treat deep vein thrombosis ... Read More

Xarelto linked to more GI bleeds than Pradaxa, Eliquis


A study published in the journal Gastroenterology pitting three newer blood thinners – Pradaxa, Xarelto and Eliquis – found that patients taking Xarelto were at a 20 percent greater risk of gastrointestinal bleeds compared to patients taking Pradaxa or Eliquis. The three blood thinners are in a new class of anticoagulants called Factor Xa inhibitors. They are used to prevent strokes in patients with the common heart rhythm condition called atrial fibrillation. They are also used to treat various blood clot-related conditions. Pradaxa contains the active ingredient dabigatran; Xarelto contains rivaroxaban; and Eliquis contains apixaban. The retrospective study used data ... Read More

New York, Louisiana considered for Eliquis MDL


Bristol-Myers Squibb Co. and Pfizer Inc., are asking the U.S. Judicial Panel on Multidistrict Litigation to centralize the 34 lawsuits alleging the companies’ blood thinner Eliquis caused bleeding injuries in the Southern District of New York, where both companies are headquartered. Doing so would improve efficiency and consistency, the drug companies argued. All but two of the plaintiffs suing Bristol-Myers Squibb and Pfizer support consolidation in a multidistrict litigation. Where to centralize the cases is the issue. New York leads in the number of cases with 16. The Eastern District of Louisiana is a distant second with four cases. But ... Read More

Pennsylvania Xarelto mass tort grew 121 percent in 2016


The number of Xarelto cases in a mass tort program in Philadelphia’s Complex Litigation Center jumped a startling 121 percent in 2016 with the addition of 664 new cases. The lawsuits claim that Xarelto makers, Johnson & Johnson, Janssen Pharmaceuticals and Bayer, did not adequately warn doctors or patients about bleeding side effects associated with the drug. They also allege the drug companies erred by marketing the drug when there was no antidote on the market to reverse the bleeding effects of the drug in the event of a bleeding emergency. Xarelto side effects include gastrointestinal bleeds, brain bleeds and ... Read More

New Xarelto lawsuit claims blood thinner caused bleeding death


The children of a Louisiana woman who allegedly bled to death after taking the blood thinner Xarelto joined a massive multidistrict litigation (MDL) accusing Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer of failing to warn of risks associated with the drug. Terrie Toups, Duane Rochelle and Patty Buras, children of Florence Bourgeois, filed their lawsuit in Louisiana federal court, where U.S. District Judge Eldon Fallon is overseeing the near-14,000 lawsuits in the multidistrict litigation against the drug companies involving bleeding risks. Xarelto, known chemically as rivaroxaban, was approved by the Food and Drug Administration (FDA) in 2011 and ... Read More